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Diffusion imaging is a promising marker of microstructural damage in neurodegenerative disorders, but interpretation of its relation-
ship with underlying neuropathology can be complex. Here, we examined both volumetric and brainmicrostructure abnormalities in 13
amnestic patients with mild cognitive impairment (MCI), who progressed to probable Alzheimer’s disease (AD) no earlier than 2 years
after baseline scanning, in order to focus on early, and hencemore sensitive, imagingmarkers.We compared them to 22 stable amnestic
MCI patients with similar cognitive performance and episodic memory impairment but who did not show progression of symptoms for
at least 3 years. Significant group differences were mainly found in the volume andmicrostructure of the left hippocampus, while white
matter group differences were also found in the body of the fornix, left fimbria, and superior longitudinal fasciculus (SLF). Diffusion
index abnormalities in the SLF were the sign of a subtle microstructural injury not detected by standard atrophy measures in the
corresponding graymatter regions. Themicrostructural measure obtained in the left hippocampus using diffusion imaging showed the
most substantial differences between the two groups andwas the best single predictor of future progression toAD.Anoptimal prediction
model (91% accuracy, 85% sensitivity, 96% specificity) was obtained by combining MRI measures and CSF protein biomarkers. These
results highlight the benefit of using the information of brain microstructural damage, in addition to traditional gray matter volume, to
detect early, subtle abnormalities inMCIprior to clinical progression toprobableADand, in combinationwithCSFmarkers, to accurately
predict such progression.
Introduction
A major goal for clinicians is to be able to detect which patients
with mild cognitive impairment (MCI) are going to progress to
Alzheimer’s disease (AD) and develop clinical symptoms of de-
mentia (Petersen, 2009).MCI has been recognized as an interme-
diate clinical stage between healthy aging andAD, but not allMCI
patients will progress to probable AD (Gauthier et al., 2006),
(Ganguli, 2006, Maioli et al., 2007). Unsurprisingly therefore,
numerous studies have investigated early signs of future progres-
sion to AD in MCI patients based on neuropsychological, CSF,
and/or imaging data (Whitwell et al., 2008, Misra et al., 2009,
Vemuri et al., 2009, Costafreda et al., 2011, Ewers et al., 2012).
However, despite some structuralMRI studies focusing on the
comparison of atrophy at baseline between the more homoge-
neous populations of stable amnestic MCI and progressingMCI,
findings have so far been variable (Winblad et al., 2004, Maioli et
al., 2007, Ferreira et al., 2011). Because small samples are the
norm in themajority of these progression versus stableMCI stud-
ies, it is all the more imperative to have well defined criteria for
the patient selection process, such as the time interval between
baseline MRI and testing for progression to AD (Whitwell et al.,
2008).
In addition, very few of these MRI-based progression versus
stable MCI studies have investigated the brain tissue microstruc-
tural properties, partly because many have drawn on the Alzhei-
mer’s Disease Neuroimaging Initiative (ADNI) dataset in which
diffusion imaging had not been acquired (Mueller et al., 2005).
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Of these few diffusion imaging studies, none found significant
difference when directly comparing the two MCI populations
(Kantarci et al., 2005, Fellgiebel et al., 2006, Haller et al., 2010,
Oishi et al., 2011). One clue might reside in the complexity of the
interpretation of the underlying neuropathology in white matter
tracts, which requires the use of sensitive diffusion indexmarkers
and image processing (Douaud et al., 2011).
In this study, we compare two groups of amnestic MCI pa-
tients showing similar cognitive performance, episodic memory
impairment, and disease duration and matched in proportion of
apolipoprotein E (APOE) 4 carriers (Farrer et al., 1997,
Trachtenberg et al., 2012). We chose to focus on amnestic MCI
patients who progressed to probable AD no earlier than 2 years
after their baseline scan (“pMCI”), in order to increase the pre-
dictive value of the imaging biomarkers evaluated here in a truly
preclinical phase of the disease. We contrasted this group with
amnestic MCI patients who were clinically stable (i.e., did not
develop AD) for at least 3 years following their first evaluation
(“sMCI”). In these two pMCI and sMCI populations, we inves-
tigated without any spatial constraint on our analyses: (1) whole-
brain gray matter volumetry using an optimized voxel-based
morphometry (VBM) approach (Douaud et al., 2007); (2) gray
matter microstructure using a voxel-based approach; and (3)
white matter microstructure using the tract-based spatial statis-
tics (TBSS) approach (Smith et al., 2006). We further tested the
potential for integrated MRI-derived and CSF protein measures
to discriminate amnestic MCI patients showing otherwise com-
parable neuropsychological performance.
Materials andMethods
Participants
This imaging study was part of the EAGLE (Early Alzheimer’s disease
Genetics—a Longitudinal Evaluation) study and was approved by the
Ethics Committee of Both Basel (Switzerland). All subjects gave written
informed consent.
In total, 64MCI patients of either sex were included in this study. CSF
was collected in polypropylene tubes, centrifuged at 3000 rpm, divided
into aliquots, and stored at 80°C within 1 h. The concentrations (in
pg/ml) of total tau (t-tau), phosphorylated tau 181 (p-tau181 ), and
-amyloid 1–42 (A1–42) were measured according to the manufacturer’s
specifications by an experienced laboratory technician using a commer-
cially available sandwich ELISA kit (Innogenetics) (Table 1). CSF sam-
ples were run in duplicates to detect variability and determine accurate
concentrations. For all subjects, comprehensive neuropsychological data
were also collected (Table 2). MCI subjects were diagnosed according to
the criteria by Winblad et al. (2004) [mini-mental state examination
(MMSE) 24/30, global CDR (clinical dementia rating) score 0.5, see
Supplementary Information of Douaud et al., 2011 for more details]. All
participants continued to be clinically monitored every 12 months
following their first visit. Of the 64 MCI patients, it appeared that 7
patients had displayed cognitive deficits due to other neurological
reasons (temporal epilepsy, semantic dementia, dementia with Lewy
bodies, hydrocephalus, alcohol-related, Parkinson’s disease) and
were therefore excluded from this study, as well as one imaging data-
set being of too poor quality. Among the 56 remaining MCI patients,
we created three groups:
–pMCI: 13 amnestic patients, who developed clinical symptoms con-
sistentwith a diagnosis of probableADat least 2 years after their first visit,
were selected to identify potential brain differences as early as possible
(on average, 2.5 years; range, 25–41 months).
–sMCI: To ensure that the group of MCI patients remained stable for
a longer period of time than the pMCI group, we selected the 22 amnestic
MCI patients who remained stable for at least 3 years following their
initial visit (on average, 4 years; range, 41–58 months) (Table 1). The
longest period of clinical progression to AD for the pMCI group was the
shortest period of confirmed clinical stability for the sMCI group (41
months).
–otherMCI: The remaining 21 MCI patients who did not correspond
to our “eligibility” criteria for the pMCI or sMCI groups were used for
classification purposes in an additional analysis (see section below, Ad-
ditional analysis: MRI and CSF classification of pMCI versus sMCI).
The pMCI or sMCI patients did not significantly differ in terms of
disease duration or neuropsychological performance and, most particu-
larly, they demonstrated comparable MMSE, episodic memory impair-
ment, and duration of symptoms at the point of scanning (Table 2). The
two pMCI and sMCI groups were also matched for the proportion of
APOE 4 carriers with an increased risk of developing AD (Farrer et al.,
1997, Trachtenberg et al., 2012) (Table 1). However, it has to be noted
that, as a result of prioritizing the inclusion of all MCI patients who
would meet our eligibility criteria of (1) a long period of progression to
probable AD for the pMCI group (n  13), thus truly focusing on the
preclinical phase of an underlying process leading toAD, and (2) a longer
period of clinical stability for the sMCI group (n  22), the groups
differed in age (7 years). To make sure that the results obtained in this
study were not mainly driven by this difference in age, we therefore
repeated all the imaging analyses for gray matter (GM) volume and dif-
fusion measures in a subset of sMCI patients (n 13, 75 6 years old, 5
female/8 male) matched for age and gender to the pMCI patients.
Imaging parameters
All patients underwent the same imaging protocol at their first
visit, including whole-brain MPRAGE T1-weighted and diffusion-
Table 1. Demographics of the two populations included in this imaging study
sMCI
(n 22)
pMCI
(n 13) p value
Age (years) 69 9 76 6 0.02
Age (years) for diffusion subjects only 69 9 76 6 0.02
Gender (F/M) 11/11 3/10 0.23a
Gender (F/M) for diffusion subjects only 10/11 3/9 0.36a
Period of follow-up/progression (months) 47.5 4.5 29.5 6.0 107
Range (months) 41–58 25–41
Disease duration (years) 5.0 4.5 3.5 2.0 0.23
APOE: Increased risk (3/4 4/4) 46% 46% —
No increased risk 54% 54% —
Education 13.5 3.5 14.0 4.5 0.72
CSF markers (pg/ml):
Tau 320 100 455 266 0.10
Phosphorylated tau 54 13 65 30 0.23
-Amyloid (A42 ) 714 256 513 221 0.02
aYates2 test.
Table 2. Neuropsychological scores in the amnestic stable sMCI and progressing
pMCI groups
sMCI
(n 22)
pMCI
(n 13) p value
MMSE 28.5 1.5 28.0 1.5 0.15
Boston Naming Test 13.5 1.0 13.5 1.5 0.70
Stroop (interference-color) 20 7 22 10 0.62
Digit span forward 6.5 1.5 7.0 2.0 0.50
Digit span backward 5.0 1.5 6.0 1.0 0.02a
Trail Making Test A 47 20 48 14 0.91
Trail Making Test B 133 62 131 51 0.89
Five-Point Test 21 8 19 7 0.50
Praxis:
Pantomime 9.5 1.0 9.5 0.5 0.35
Sensory apraxia 10.0 0.5 10.0 0.5 0.91
Imitation 12.0 0.5 11.5 0.5 0.07
Bucco-facial 6.0 0.0 6.0 0.5 0.34
Verbal fluency (letters) 12.5 4.5 12.0 4.5 0.70
Verbal fluency (category) 22.0 5.5 18.0 5.0 0.04
Verbal delayed recall (normalized) 1.6 0.9 1.9 1.0 0.38
aThe pMCI group performed better at this test.
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weighted scans using a 3T Allegra MR imager (Siemens) with a standard
quadrature head coil and maximum 40 mT  m1 gradient capability.
T1-weighted images were obtained with an MPRAGE sequence (TE/
TI/TR 3.5/1000/2150 ms, 1.1 1.1 1.1 mm3). Diffusion-weighted
images were obtained using echo-planar imaging (SE-EPI, TE/TR 
89/7000 ms, 54 axial slices, bandwidth 2056 Hz/voxel, 2.5 2.5 2.5
mm3) with 30 isotropically distributed orientations for the diffusion-
sensitizing gradients at a b value of 900 s  mm2 and 6 b 0 images. To
increase signal-to-noise ratio, scanning was repeated twice and both
scans were corrected for head motion and eddy currents using affine
registration before being combined.
Direct comparisons between pMCI and sMCI: image processing
and statistical analysis
Structural imaging. We carried out an optimized VBM protocol using
FMRIB Software Library (FSL) tools (Smith et al., 2004, Douaud et al.,
2007; fsl.fmrib.ox.ac.uk/fsl/fslwiki/FSLVBM) to assess the significant dif-
ferences in the distribution of gray matter volume between pMCI and
sMCI. First, a left–right symmetric, study-specific, and unbiased GM
template was built from the 13 pMCI patients and from 13 (a random
subset) sMCI patients images. Second, the full set of all 35 GM images
was nonlinearly spatially normalized onto this study-specific template,
“modulated” to compensate for the local contraction/enlargement due
to the nonlinear component of the transformation, and smoothed with
an isotropic Gaussian kernel with a sigma of 3 mm (7 mm FWHM)
(Good et al., 2001).
Diffusion imaging. Fractional anisotropy (FA) maps—obtained in 12
and 21 MCI subjects, respectively, as diffusion images could not be ac-
quired on oneMCI patient for each group (coil failure)—were generated
using FSL (Smith et al., 2004). Differences in diffusion tensor imaging
(DTI) indices in the white matter were assessed using TBSS, a voxelwise
approach that increases the sensitivity and interpretability of the results
compared with approaches that are based purely on nonlinear registra-
tion (Smith et al., 2006). Because of substantial ventricular enlargement
that was seen in many subjects in this study, we created a study-specific
FA template by: (1) nonlinearly registering 12 pMCI FA images and
12 (a random subset) sMCI FA images to an FA template in the MNI
space derived from 58 healthy subjects (fsl.fmrib.ox.ac.uk/fsl/fslwiki/
FMRIB58_FA); and (2) subsequently averaging those 24 FA images. Sim-
ilarly to the approach used in FSL-VBM, this study-specific FA template
was built with the same number of subjects from each MCI population.
Figure 1. Whole-brain significant GM volume differences at baseline between pMCI and
sMCI. Despite the pMCI patients being scanned on average 2.5 years prior to their clinical pro-
gression toAD, the FSL-VBManalysis revealed significantly smallerGMvolumeessentially in the
left amygdalo-hippocampal complex compared with sMCI ( p 0.01 corrected for multiple
comparisons). Results are overlaid onto the average of all nonlinearly registered GM segmen-
tations. Radiological convention (left is right).
Figure 2. Voxel-based (as opposed to “skeletonized”) significant MD differences at
baseline. Traditional voxel-based analysis revealed markedly higher MD in pMCI primarily
localized to the left amygdalo-hippocampal complex ( p  0.05 corrected for multiple
comparisons). Results are overlaid onto the average of all nonlinearly registered FA im-
ages. Radiological convention (left is right).
Figure 3. Whole-brain significantWM “skeletonized”MO and FA differences between pMCI
and sMCI groups at baseline. A, B, TBSS revealed significant differences at baseline between
pMCI and sMCI with lower MO in the body of the fornix extending to the left fimbria (A, in red)
andhigherMO in the centrum semiovalewhere SLF and CST cross (B, in light blue-purple) ( p
0.05 corrected for multiple comparisons). C,D, FA exhibited the same qualitative changes than
MO (C, lower FA in orange; D, higher FA in dark blue), although these were just below the
statistical threshold ( p 0.08 corrected for multiple comparisons). Radiological convention
(left is right).
Douaud et al. • Early Brain Microstructure Abnormalities in MCI J. Neurosci., January 30, 2013 • 33(5):2147–2155 • 2149
This was done to avoid any bias that would
have consisted in a more accurate nonlinear
registration for one of the groups, subsequently
making it impossible to distinguish pathologi-
cally meaningful differences from registration-
related differences. Then, we nonlinearly
registered the 33 original FA scans to this
study-specific FA template. The nearest maxi-
mum FA values of each registered FA image
were projected onto a white matter skeleton
derived from the FMRIB58 template and
thresholded at FA0.2. This projection step
aims to remove possible residual effect of
cross-subject spatial variability after the non-
linear registration.
We then analyzed with TBSS the mean dif-
fusivity (MD) and mode of anisotropy (MO)
images using the resulting warp fields from the
FA analysis. We chose to study MO, as it ap-
pears to be sensitive in capturing subtle differ-
ences in the white matter, in particular in
crossing fiber regions, which contrasts with ax-
ial and radial diffusivities that prove difficult to
interpret in such regions that can encompass
up to 90% of the brain (Wheeler-Kingshott
and Cercignani, 2009, Jeurissen et al., 2012).
Indeed, in a previous diffusion study looking at
the white matter in 61 controls, 56MCI partic-
ipants and 53 AD patients (Douaud et al.,
2011), no difference could be found when in-
vestigating whole-brain diffusion indices of
mean diffusivity and fractional anisotropy be-
tween MCI and healthy subjects, but we re-
vealed some alteration in a single region of
crossing fibers in the centrum semiovale,
showing a higher mode of anisotropy (Ennis
and Kindlmann, 2006).
Finally, we also investigated differences in GM diffusion—an analysis
that is not possible via the TBSS approach, which focuses onwhitematter
(WM) diffusion. The main pitfall of applying a simpler voxelwise ap-
proach is that it is not straightforward to robustly account for inaccura-
cies in the nonlinear registration (with respect to perfectly aligning gray
matter across subjects and avoiding partial voluming biases). Bearing this
caveat inmind, we looked at voxelwise, as opposed to “skeletonized,” FA,
MD, andMO values in the GM.We analyzed the same images processed
with TBSS, except that the statistical tests were carried out on the images
that had not gone through the final step of projection onto the white
matter skeleton.
Statistical analysis.We used permutation-based nonparametric infer-
ence within the framework of the general linear model to look for signif-
icant abnormalities across the two diagnosis groups (Nichols and
Holmes, 2002). Results were considered significant for p  0.05, cor-
rected for multiple comparisons after initial cluster-forming threshold-
ing at p 0.05 uncorrected.We also looked at correlations between each
of the significant MRI-derived measures using datamind, a statistical
interface using R developed in BrainVISA (Duchesnay et al., 2004).
Additional analysis: MRI and CSF classification of pMCI
versus sMCI
Circular inference concerns prevented us from using the significant dif-
ferences found when directly comparing pMCI and sMCI as regions of
interest (ROIs) for classification purposes. A common alternative ap-
proach (Teipel et al., 2007, Fennema-Notestine et al., 2009, Davatzikos et
al., 2011, Oishi et al., 2011) is to use differences found between healthy
controls andADpatients to define ROIs that will be used to extract values
in the MCI groups. There is strong evidence, however, that the progres-
sion of atrophy from healthy state to AD is a highly spatially and tempo-
rally nonlinear process (Ferreira et al., 2011, Tondelli et al., 2012).
Therefore, we chose instead to derive the ROIs based on imaging differ-
ences found between MCI and AD: our “otherMCI” group and, on the
other hand, 59 AD patients without a vascular component. The
otherMCI group was composed of the 21 participants who did not meet
the “eligibility” criteria for our pMCI and sMCI groups (nine had not yet
been clinically followed up for long enough at the time of this study, three
were non-amnestic, and nine had progressed to AD in 2 years after
scanning). The diagnosis of probable AD for the 59 patients composing
the AD group was made when both the DSM-IV criteria (American
Psychiatric Association, 1994) and the NINCDS-ADRDA criteria
(McKhann et al., 1984) were fulfilled (see Douaud et al., 2011 for more
details on these patients).
For this classification approach, we carried out the same GM vol-
ume and diffusion microstructural images preprocessing as described
in the previous section. We then tested the classification accuracy of
MRI measures (macrostructural GM volume and diffusion micro-
structure) and CSF protein concentrations when attempting to clas-
sify all 33 amnestic patients into either the pMCI or sMCI group using
a linear discriminant analysis and leave-one-out cross-validation in
datamind (R).
Results
Macrostructural differences between pMCI and sMCI at
baseline: GM volume
We identified one cluster of significantly smaller GM volume
in pMCI compared with sMCI (Fig. 1). This region primarily
included the left cornu ammonis of the hippocampus, left
laterobasal group of the amygdala, and the left parahippocam-
pal gyrus extending to the temporal pole as identified on the
Ju¨lich atlas (Amunts et al., 2005) (fsl.fmrib.ox.ac.uk/fsl/
fslwiki/Atlases).
Figure 4. All significant MRI-derived measures in sMCI (yellow) and pMCI (red). Values obtained in those regions showing
significant differences between the pMCI and sMCI: VOL, GMvolume smaller in pMCI essentially in the left hippocampus;MO (SLF),
mode of anisotropy higher in pMCI in the SLF; MO (fornix), mode of anisotropy lower in pMCI in the fornix; MD, mean diffusivity
higher in pMCI essentially in the left hippocampus (109 m 2  s1).
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Microstructural differences between pMCI and sMCI at
baseline: diffusion indices
Voxel-based diffusion analysis
We found significantly higher MD in pMCI compared with
sMCI, which was essentially confined to the left hippocampus
and amygdala (Fig. 2). We found no significant voxel-based dif-
ferences in MO or FA.
TBSS diffusion analysis
We found two significant regions of difference between pMCI
and sMCI usingMO. First, we found lowerMO in the body of the
fornix noticeably extending to the left hippocampus (left fimbria)
in pMCI relative to sMCI (Fig. 3A). Second, we found a signifi-
cantly higher MO in the centrum semiovale where the superior
longitudinal fasciculus (SLF) and the corticospinal tract (CST)
cross in pMCI relative to sMCI (Fig. 3B). We did not find any
significant differences in FA or MD on the TBSS white matter
skeleton between the two groups after correction for multiple
comparisons. However, FA exhibited the same qualitative differ-
ences than MO just below threshold for statistical significance
(Fig. 3C,D).
As there is considerable enlargement of the ventricles in these
patients, we confirmed that the results obtained with TBSS, espe-
cially those in the fornix, were interpretable by “deprojecting” all
voxels showing significantly higher or lower MO from the white
matter skeleton-space back into each subject’s full standard-
space FA image. This confirmed that the tracts identified on the
skeletonized differencemaps correspondedwell to the fornix and
to the region where SLF and CST cross in the centrum semiovale
(data not shown).
Macrostructural andmicrostructural differences separate
pMCI and sMCI at baseline
When looking in the regions defined by the significant differences
between pMCI and sMCI in both GM volume (VOL) and diffu-
sion (MD), as well as inWM diffusion (MO), MRI-derived mea-
sures proved to differentiate well patients in the pMCI group
from those in the sMCI group at baseline (Fig. 4).
When considering the spread of these significant MRI mea-
sures, the sMCI patients who had similar imaging values as those
of the pMCI patients for their GM volume and MO diffusion
(x-axis, Fig. 5) showed nonetheless very distinct MD diffusion
values compared to those of pMCI ( y-axis, Fig. 5). In all in-
stances, it thus appeared that, following the direction of progres-
sion toward AD, what seemed to differentiate the sMCI patients
from pMCI was the microstructural diffusion measure of MD in
their left hippocampus, above and beyond the traditional macro-
structural measure of GM volume reduction of the same struc-
ture in particular.
We also found a significantly steeper slope in the correlation
between diffusionmeasures in the hippocampus and in the white
matter (MDwithMO in the SLF: p 0.004; MDwithMO in the
fornix: p 0.017) in pMCI compared with sMCI (Fig. 5).
Early prediction of progression to AD
One important question that we could not answer directly from
this dataset (because of the problem of circularity, or “double
dipping”) was the predictive value of these MRI-derived mea-
sures using these regions of significant group differences. We
therefore estimated group differences between an MCI group
distinct to the pMCI and sMCI groups and a large AD group to
obtain the ROIs used to classify our primary groups of interest
(sMCI and pMCI). We obtained significantly smaller GM vol-
ume in the AD group compared with the MCI group mainly in
the left amygdalo-hippocampal complex and bilaterally in the
retrolimbic region of the precuneus (data not shown). There was
also significantly higher MO in the centrum semiovale in the AD
group, but no significantly lower MO in the fornix after correc-
tion for multiple comparisons. We finally found significantly
higher MD in the AD group mainly in the left cornu ammonis
and laterobasal group, as well as bilaterally in the posterior den-
tate gyrus (data not shown).
Figure 5. Scatterplots of all significant MRI-derived measures in sMCI (yellow) and pMCI
(red).MD values (essentially from the left hippocampus) are plotted against the following: Top,
GM volume (VOL) essentially from the left hippocampus; Middle, MO from the fornix; Bottom,
MO from the SLF. Top, The relationship between VOL and MD (106 m 2  s1) demon-
strated a very fine stratification of the two groups with comparable slopes when fitting a linear
model for each group considered independently. Middle, The relationship between lower MO
andMD showed a slightly steeper slope for the pMCI groupwhen fitting a linearmodel for each
group independently ( p  0.017). Bottom, The relationship between higher MO and MD
clearly showed a steeper slope for the pMCI group ( p 0.004).
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Using these regions of significant differences as ROIs to
extract values from the pMCI and sMCI groups, we found that
MD gave the highest classification accuracy of all imaging and
CSF measures (77%), when we considered each measure as
single predictor (Table 3). CSF protein biomarker concentra-
tions had similar or lower discrimination accuracies, with tau
concentration providing the best accuracy of the CSF markers
(74%) (Table 3). Finally, by combining imaging and CSF
markers, namely by using GM volume (66% as single predic-
tor) and a composite of diffusion measures (MO MD, 69%
as single predictor) together with a composite of CSF mea-
sures (tau/A42, 74% as single predictor), we could classify
accurately 91% (CI, 75–97) of the amnestic MCI patients with
85% sensitivity and 96% specificity and with a diagnostic odds
ratio of 116 (CI, 7–4547) (Table 3).
Discussion
All MRI-derived measures, GM volume,
MD, and MO, converged to demonstrate
the strong involvement of the left hip-
pocampus in the progression from MCI
to AD. We found indeed a markedly
smaller GM volume and higher MD in
this structure accompanied by lower MO
in the body of the fornix extending into
the left fimbria. The significantly smaller
GM volume in the left hippocampus of
pMCI is in line with the recent finding of a
VBM meta-analysis on the GM volume
predictors of progression to AD (Ferreira
et al., 2011) in which a single cluster was
found in the left hippocampus with coor-
dinates corresponding to ourmain cluster
(Fig. 1). Notably, the smaller GM volume
was not sufficient to characterize the pro-
gression toward AD (Fig. 5, top): the
sMCI patients who had similar left hip-
pocampal volume to the pMCI patients
showed nonetheless lower MD values in
this structure than pMCI patients. Higher
MD values in the hippocampus of AD patients compared with
healthy controls have previously been shown to remain when
controlling for hippocampal volume, demonstrating that diffu-
sion metrics can provide independent information beyond hip-
pocampal volume alone (Salat et al., 2010). In addition, two
studies investigating differences between sMCI and pMCI using
ROIs in the hippocampus found a trend for higher MD in pMCI
(Kantarci et al., 2005, Fellgiebel et al., 2006). If the origin of such
higher MD in pMCI cannot be unambiguously elucidated in the
present study, it has been related to astrocytosis in a recent com-
bined study of DTI and histology in a model of Huntington’s
disease (Van Camp et al., 2012). Astrocytosis is a known neuro-
pathological feature of AD and has been consistently shown to be
related to A deposition and neuritic change in the disease
(Selkoe, 1991, Cairns et al., 1992, Pike et al., 1994, Steele and
Robinson, 2010, Santillo et al., 2011). Speculatively, it is therefore
possible that higher MD values, above and beyond the volume
reduction in the left hippocampus of pMCI, are a sign of the
reactive astroglia typical of AD stage. The fact that the two MCI
groups had similar duration of symptoms (if anything, a slightly
shorter duration of symptoms in pMCI, Table 1) argues in favor
of a more aggressive neurodegenerative process in pMCI (Fer-
reira et al., 2011).Of note, a recent study showed that injury to the
right hippocampus may be characteristic of a transition from
healthy aging to MCI (Tondelli et al., 2012), while we show here
that injury to the left hippocampus (as demonstrated by both
higher MD and smaller GM volume) may mark the final transi-
tion from MCI to AD.
For the first time we found evidence of white matter differ-
ences at baseline between pMCI and sMCI groups in the body of
the fornix and its left fimbria and in the centrum semiovale SLF
(where it crosses the CST). The fornix has been consistently
shown in animal studies to be involved in spatial memory forma-
tion and visuospatial memory acquisition (Thomas et al., 2011),
but the narrowness and location of this tract following the lateral
ventricles makes it prone to partial volume effect and very diffi-
cult to segment. A few imaging studies have nonetheless demon-
strated either a smaller volume or lower FA in this tract inMCI or
AD (Copenhaver et al., 2006, Mielke et al., 2009, Zhuang et al.,
2010, Agosta et al., 2011).Measures in the SLF, on the other hand,
do not suffer from the drawback of partial voluming. This tract,
in which lesions result in deficit of visuospatial attention and
workingmemory (Makris et al., 2005, Hoeft et al., 2007), appears
in our cohort to be the only white matter pathway stratifying the
progression to AD every step of the way from healthy aging: we
previously found that it was showing significant differences be-
Figure6. Whole-brain group comparisons between pMCI and sMCI, after excluding nine sMCI participants from the analyses to
match the groups for age and gender. Despite an inherent loss of statistical power in the statistical model due to the loss of these
nine subjects, the spatial pattern of the results for each modality was extremely similar between the analyses with the larger
dataset (in green) and the reduced, age-matched dataset (in orange). A, Higher MO values; B, lower MO values; C, higher MD
values; and D, smaller GM volume in pMCI compared with sMCI ( p 0.05 uncorrected, except for C: p 0.01, uncorrected).
Table 3. Classification accuracy in % for MRI measures and CSF protein
concentrationmeasures
Accuracy (CI) Sensitivity Specificity
VOL 66 (50–80) 39 82
MO 66 (49–81) 46 77
MD 77 (59–89) 62 86
VOLMOMD 69 (51–84) 54 77
A42 60 (46–75) 31 77
Tau 74 (56–88) 39 96
p-tau 66 (54–75) 23 91
A42 tau p-tau 69 (53–81) 39 86
VOL/MD 63 (47–78) 39 77
MOMD 69 (52–83) 46 82
tau/A42 74 (58–84) 46 91
(VOL/MD or VOL)MOMD tau/A42 91 (75–97) 85 96
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tween healthy, elderly,MCI patients and AD patients (Douaud et
al., 2011), and we demonstrate here that it also proves to separate
sMCI and pMCI. A recent study has also shown that diffusion
differences between non-amnestic and amnestic MCI are found
where SLF and CST cross (O’Dwyer et al., 2011). As the GM loss
in pMCI compared with sMCI wasmostly confined to themedial
temporal lobe, the impairment of the SLF is notably the evidence
of a subtle degeneration not (yet) detectedmacroscopically in the
corresponding GM regions. Interestingly, however, we found a
high correlation between the SLF and all measures associated
with the hippocampus (GM volume: r0.69, p 105; MD:
r 0.77, p 105; MO in the fornix and left fimbria: r0.84,
p 105), providing de facto an intermediary between elements
of the Papez circuit (hippocampus and fornix) and of the lateral
heteromodal cortex (temporoparietal regions, DLPFC) con-
nected via the SLF (Mesulam, 1998). The disruption of the SLF
might therefore be a key element that reconciles the apparent
discrepancy observed in AD between the consistent structural
alteration seen in the hippocampus and the functional impair-
ment identified in heteromodal association areas (Minoshima et
al., 1997, Lustig et al., 2003, Greicius et al., 2004, Buckner et al.,
2005, Villain et al., 2008, Buckner et al., 2009, Schroeter et al.,
2009).
All three MRI measures showed a very strong difference and
limited overlap between pMCI and sMCI. A formal confirmation
of the benefit of using MRI measures was that considering alone
the best CSF predictors (tau or tau/A42) led to 74% accuracy
(CI, 56–88), but combining CSFwithMRI volume and diffusion
measures led to 91% accuracy (CI, 75 – 97). A qualitatively sim-
ilar example can be found in one of the largest MCI studies, in
which 69 progressing and 170 stable MCI patients were followed
up for a maximum of 12months (Davatzikos et al., 2011). In this
setting, combining MRI volumetric measures to the best CSF
measure (tau) led to the best classification accuracy (62%). Ad-
ditionally, it is reasonable to hope that defining ROIs using a
training dataset of pMCI and sMCI (instead of contrasting an
entirely different MCI group with AD patients as done in this
study), or indeed directly using an ROI of the left hippocampus,
would lead to an even better prediction accuracy than that
achieved here (Desikan et al., 2009).
One limitation (in terms of sensitivity, but not statistical va-
lidity) of our study is the limited sample size for each group. We
note, though, that the implication of using valid statistical testing
(in our case, using permutation-based nonparametric inference
fully corrected for multiple comparisons over space) is that a
significant result in a small sample is statistically correct, and the
actual effect observed has to be larger for a small group to reach
significance than it would have needed to be for a larger group
(Friston, 2012). Another limitation is that both populations were
not matched for age, as we chose instead to focus on a clear
preclinical phase of the underlying process leading to AD and to
make sure that both groups were truly different, as the longest
period of progression to AD for the pMCI group was the shortest
period of confirmed clinical stability for the sMCI group. This
provided us with 13 and 22 patients in each group who were
matched for their proportion of APOE 4 carriers, and who did
not show any significant differences in duration of symptoms or
in their neuropsychological assessment, including episodicmemory
performance. We therefore additionally reran all analyses in a
matchedsubsetofpatients (n26 in total).Despite the inherent loss
of statistical power due to the loss of nine patients, the qualitative
patternof resultswas extremely similar for each imagingmodality to
those obtained on the larger dataset (n 35 in total, Fig. 6).
Our findings from structural and diffusion imaging converge
to provide evidence of the critical involvement of the left hip-
pocampus and SLF in the progression fromMCI to AD, and this
as early as 2.5 years prior to such progression.Direct group compar-
isons provide MRI-derived differences that separate stable and
progressing MCI very well despite both populations showing com-
parable neuropsychological performance. Best prediction accuracy
of 91% is obtained by combiningMRI and CSFmeasures following
the observationsmade by Jack and others (Vemuri et al., 2009, Jack
et al., 2010, Petersen et al., 2010). We also demonstrate that the
microstructural measure obtained in the left hippocampus using
diffusion imaging shows themost substantial differences between
the two groups beyond that of the macrostructural measure of
atrophy in the same structure and is the best single predictor of
future progression to AD. Diffusion abnormalities in the SLF are
also the mark of a subtle microstructural injury not detected by
traditional volumetric approach in the GM regions connected by
the SLF. To summarize, at theMCI stage, when patientsmay seek
medical advice for the first time, MRI measures of degeneration
—andmore specifically ofmicrostructural damage—are able to
detect the patients whowill develop clinical symptoms consistent
with probable AD at least 2 years later. This period of time may
offer an opportunity for potential treatments to be effective in
slowing the disease progression (Miller, 2012).
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